New HIV drug lipovirtide passes first safety check in small study
NCT ID NCT04592315
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single injection of a new drug, lipovirtide, in 46 HIV-positive adults who had never taken antiviral medication. The main goal was to check if the drug is safe and how the body processes it. This is a first step toward finding new treatments to control HIV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing You'an Hospital, Beijing Medical University
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?